{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:56:18Z","timestamp":1794264978629,"version":"4.9.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["F223018186C"],"award-info":[{"award-number":["F223018186C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Teriparatide is one of several generic peptides named in a recent Food and Drug Administration (FDA) guidance (FDA-2017-D-5767-0002), which outlines a potential strategy to inform immunogenicity risk assessment for synthetic generic peptides without requiring clinical studies. Specifically, the guidance states that for abbreviated new drug applications (ANDAs), once the sameness of the active pharmaceutical ingredient (API) between the generic product and the reference listed drug is established, developers can mitigate the residual risk of unwanted immunogenicity response by using\n                    <jats:italic>in silico<\/jats:italic>\n                    and\n                    <jats:italic>in vitro<\/jats:italic>\n                    tools to characterize differences in product- and process-related impurities between the reference and generic drug products. Regarding product-related impurities, a stated concern is that sequence modifications may create new T-cell epitopes capable of driving unwanted immune responses. Specifically, the guidance sets limits for the relative abundance of each impurity and requests that any new impurity above a certain concentration threshold be evaluated for potential T-cell-driven immunogenicity using orthogonal methods that assess both human leukocyte antigen (HLA) binding and the capacity to elicit a T-cell response. One such orthogonal immunogenicity risk assessment approach was applied to teriparatide (TPT) and several theoretical or observed product-related impurities in the case study described here. First, the immunogenic potential of TPT and selected impurities was assessed using three\n                    <jats:italic>in silico<\/jats:italic>\n                    tools: EpiMatrix, ClustiMer, and JanusMatrix. Second, an\n                    <jats:italic>in vitro<\/jats:italic>\n                    method was used to evaluate the binding affinity of TPT and the selected TPT impurities to different class II HLA-DRs\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Third, a human peripheral blood mononuclear cell (PBMC) T-cell assay compared T-cell proliferation in response to individual impurities or the reference teriparatide drug product, Forteo\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ,\n                    <jats:italic>in vitro<\/jats:italic>\n                    . The orthogonal approaches identified multiple impurities as more immunogenic than TPT. In a novel finding, the\n                    <jats:italic>in silico<\/jats:italic>\n                    analysis revealed a potentially tolerogenic sequence in TPT, which correlated with lower-than-expected\n                    <jats:italic>de novo<\/jats:italic>\n                    immune responses to TPT\n                    <jats:italic>in vitro<\/jats:italic>\n                    . The analysis and methods described in this case study may help assess the relative risk of impurities and help identify those with the potential to increase the immunogenicity risk of a generic peptide.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1730346","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:46:51Z","timestamp":1765208811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products"],"prefix":"10.3389","volume":"16","author":[{"given":"Aimee E.","family":"Mattei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lelias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah","family":"Miah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina E.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Verthelyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"De Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","unstructured":"FORTEO package insert\n          \n          \n          \n          2021"},{"key":"B2","volume-title":"ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin - May 2021","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103714","article-title":"Immunogenicity risk assessment of synthetic peptide drugs and their impurities","volume":"28","author":"De Groot","year":"2023","journal-title":"Drug Discov Today"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1608401","article-title":"Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors","volume":"16","author":"Puig","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2333729","article-title":"In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies","volume":"16","author":"Mattei","year":"2024","journal-title":"MAbs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24615","article-title":"The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix","volume":"9","author":"Moise","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00173-X","article-title":"Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix","volume":"16","author":"Schafer","year":"1998","journal-title":"Vaccine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fddsv.2022.952326","article-title":"In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements","volume":"2","author":"Mattei","year":"2022","journal-title":"Front Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(03)00390-6","article-title":"Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach","volume":"21","author":"De Groot","year":"2003","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2014.08.026","article-title":"HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients","volume":"62","author":"Losikoff","year":"2015","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012444","article-title":"Modification of regulatory T cell epitopes promotes effector T cell responses to aspartyl\/asparaginyl \u03b2-hydroxylase","volume":"23","author":"Wirsching","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00852.x","article-title":"Epitope spreading: protection from pathogens, but propagation of autoimmunity","volume":"26","author":"Powell","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2011.06.005","article-title":"Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model","volume":"37","author":"Hintermann","year":"2011","journal-title":"J Autoimmun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOCI.0000040928.67495.52","article-title":"Humoral epitope-spreading following immunization with a HER-2\/neu peptide based vaccine in cancer patients","volume":"24","author":"Disis","year":"2004","journal-title":"J Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(97)00147-8","article-title":"Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope","volume":"34","author":"Dalum","year":"1997","journal-title":"Mol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2009.07.001","article-title":"T cell epitope: Friend or Foe? Immunogenicity of biologics in context","volume":"61","author":"Weber","year":"2009","journal-title":"Adv Drug Delivery Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1247876","article-title":"Identification of immunodominant T cell epitopes induced by natural Zika virus infection","volume":"14","author":"Eickhoff","year":"2023","journal-title":"Front Immunol"},{"key":"B18","article-title":"Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if machine (WhIM)","author":"Mattei","year":"2023"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jpba.2014.06.012","article-title":"Related impurities in peptide medicines","volume":"101","author":"D\u2019Hondt","year":"2014","journal-title":"J Pharm BioMed Anal"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01301","article-title":"T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation\u2013updated consensus and review 2020","volume":"11","author":"Jawa","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052471","article-title":"Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide","volume":"203","author":"Steere","year":"2006","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4172\/1745-7580.1000049","article-title":"An integrated genomic and immunoinformatic approach to H. pylori Vaccine Design","volume":"7","author":"Ardito","year":"2011","journal-title":"Immunome Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.039","article-title":"Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine","volume":"25","author":"McMurry","year":"2007","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1363139","article-title":"Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods","volume":"15","author":"Roberts","year":"2024","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00004-07","article-title":"Ex vivo monitoring of antigen-specific CD4+ T cells after recall immunization with tetanus toxoid","volume":"14","author":"Barbey","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-138073","article-title":"Activation of natural regulatory T cells by IgG Fc\u2013derived peptide \u201cTregitopes","volume":"112","author":"De Groot","year":"2008","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2014.10.012","article-title":"Tregitope: immunomodulation powerhouse","volume":"75","author":"Cousens","year":"2014","journal-title":"Hum Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/621693","article-title":"Application of igG-derived natural treg epitopes (IgG tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes","volume":"2013","author":"Cousens","year":"2013","journal-title":"J Diabetes Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9762-4","article-title":"In vitro and in vivo studies of igG-derived treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity","volume":"33","author":"Cousens","year":"2013","journal-title":"J Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/256460","article-title":"Potential application of tregitopes as immunomodulating agents in multiple sclerosis","volume":"2011","author":"Elyaman","year":"2011","journal-title":"Neurol Res Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1286","article-title":"Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools","volume":"9","author":"Lamberth","year":"2017","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26247461","article-title":"An in vitro assessment of immunostimulatory responses to ten model innate immune response modulating impurities (IIRMIs) and peptide drug product, teriparatide","volume":"26","author":"Holley","year":"2021","journal-title":"Molecules"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108661","article-title":"Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses","volume":"224","author":"De Groot","year":"2021","journal-title":"Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1290688","article-title":"A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses","volume":"14","author":"Miah","year":"2023","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO;2-O","article-title":"Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation","volume":"27","author":"Caruso","year":"1997","journal-title":"Cytometry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1052197","article-title":"H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance","volume":"11","author":"Liu","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B37","article-title":"Alternative models: from humanized mice to microphysiological systems and beyond","author":"Howard","year":"2025"},{"key":"B38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2020.10.009","article-title":"The multifaceted functions of follicular regulatory T cells","volume":"67","author":"Sage","year":"2020","journal-title":"Curr Opin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1730346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:46:54Z","timestamp":1765208814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1730346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1730346"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1730346","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2025.1730346.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1730346"}}